EU Commission Approves Pfizer’s Takeover of Seagen
The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.
Seagen
FTC Intervention in Amgen-Horizon Deal Stuns Biopharma
The US Federal Trade Commission’s lawsuit to potentially block the $27.8 merger of Amgen and Horizon Therapeutics is creating heightened concern in the international biopharma sector.
Pfizer Takes Seagen for $43 Billion
Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks.
Pfizer in Talks to Take Cancer Biotech Seagen
Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in the Wall Street Journal that cited people familiar with the matter. The purchase price could potentially be more than $30 billion.
